AUSTIN, Texas, June 6 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today that its management has been authorized to take steps to effect a dual listing for the company on both the NASDAQ and London Stock Exchange (LSE). The LSE listing decision reflects Introgen's ongoing discussions with potential international distribution partners, including European entities, as well as the expansion of its European investor base. In December 2004, Introgen placed shares with European institutions to increase its already significant European investor base. Introgen's first underwritten offering in 1997 was sold exclusively to European institutions. In addition, the Company recently announced that it won an important and final European Patent Office case related to its p53 tumor suppressor therapy. The patent ruling results in a clear path to commercialization of several of Introgen's product candidates in Europe that utilize p53 as an active component, including ADVEXIN(R), INGN 225, INGN 234 and INGN 402. "A listing on the London Stock Exchange represents the next step in a series of actions that Introgen plans to take to leverage its assets on a global basis -- particularly in Europe and Asia. ADVEXIN, as well as our other product candidates, represent first-in-class products aimed at treating cancer. We want to maximize shareholder value with optimum commercial strategies around the world," said David Nance, Chief Executive Officer of Introgen. "We are building a presence in Europe, having conducted some of our trials here and worked with European regulatory authorities on the global registration program for ADVEXIN. In addition, we have developed a strong global patent portfolio. We believe that a listing on the LSE demonstrates our commitment to facilitating investment in Introgen by European investors, as well as in developing a stronger European presence for the company." About Introgen Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using non-integrating tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates a multiple manufacturing facilities including a commercial scale cGMP manufacturing facility. Certain statements in this press release that are not strictly historical may be "forward-looking" statements, which are based on current expectations and entail various risks and uncertainties. Such forward-looking statements include, but are not limited to, those relating to Introgen's future success with its clinical development programs for ADVEXIN for the treatment of cancer and the listing of Introgen's stock on the London Stock Exchange. There can be no assurance that Introgen will be able to commercially develop gene-based drugs, that necessary regulatory approvals will be obtained or that any clinical trials or studies undertaken will be successful or that the proposed treatments will prove to be safe and/or effective. The actual results may differ from those described in this press release due to risks and uncertainties that exist in Introgen's operations and business environment, including, but not limited to, Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, Introgen's dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its annual report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2005 and its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2005. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof. Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: http://www.introgen.com. Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: firstname.lastname@example.org
SOURCE Introgen Therapeutics, Inc.